Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book
  1. Brieflands
  2. journals
  3. Journal of Advanced Immunopharmacology
  4. Articles

  5. Tebentafusp: The First FDA-approved Monoclonal Antibody for Cancer Treatment in 2022
  6. Scopus by Title (Ref)

Journal of Advanced Immunopharmacology

homeHome
play_arrowCurrent IssuelistArchiveformat_indent_increaseIn Presscheck_circleAccepted ManuscriptssearchSearch
helpInstruction
infoJournal InformationgroupsBoards and EditorsshareIndexing and Listing Sourcesbar_chartJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Malpractice Statementassignment_indReviewer and AE Registration FormcampaignAnnouncement: New Journal TitleemailSupportphoneContact Us
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Current landscape of innovative drug development and regulatory support in China

- Tan R. , et al.

2. A Brief Overview of Uveal Melanoma Treatment Methods with a Focus on the Latest Advances

- Wdowiak K. , et al.

3. Pharmacological Profile of FDA-Approved Orphan Drugs in the Year 2022

- Goyal P.K. , et al.

4. New immunotherapy approaches as the most effective treatment for uveal melanoma

- Eteghadi A. , et al.

5. Pharmacological Profile of Novel Anti-cancer Drugs Approved by USFDA in 2022: A Review

- Sangwan K. , et al.

HomeInstruction

Articles

  • Current Issue
  • Archive
  • In Press
  • Accepted Manuscripts
  • Search

About Journal

  • Journal Information
  • Boards and Editors
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Announcement: New Journal Title
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.